AGP Executive Report
Last update: 11 hours agoRare disease treatment in the spotlight: The European Commission has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), the first pharmacological option in the EU for early intervention in childhood cerebral adrenoleukodystrophy (cALD) for boys aged 2–12 with Gd-negative brain lesions—an advance that could help slow irreversible neurodegeneration. US drug tariffs—targeted relief for specialty medicines: The US Commerce Department says certain specialty drugs and ingredients imported from India and 19 other jurisdictions (including Liechtenstein) will face 0% ad valorem tariffs under a Section 232 framework, covering categories like orphan drugs, fertility treatments, cell and gene therapies, and antibody-drug conjugates. Healthcare staffing pressure: A “50:50 rule” limiting non-EEA workers to half of an organisation’s workforce is set to be temporarily relaxed to ease healthcare staff shortages, with nursing homes and home-care services highlighted as under strain. Policy debate in Liechtenstein: The European Evangelical Alliance raised concerns after Liechtenstein’s parliament narrowly backed a citizen-led initiative to legalise abortion in the first 12 weeks.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
